#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Severe myoclonic epilepsy of infancy Peritoneal neoplasm Biliary cancer metastatic Fms-like tyrosine kinase 3 positive Alport's syndrome Squamous cell carcinoma of the hypopharynx Adrenogenital syndrome Erdheim-Chester disease Encephalopathy neonatal Ocular lymphoma Gastroenteropancreatic neuroendocrine tumour disease Hypersensitivity pneumonitis Mantle cell lymphoma refractory Extra-osseous Ewing's sarcoma recurrent Juvenile psoriatic arthritis More trials…

    Learn about Rare Diseases

    IgA nephropathy – Trials in Disease Pulmonary sarcoidosis – Basic Information Basal cell naevus syndrome – Basic Information Atypical teratoid/rhabdoid tumour of CNS – Diagnostics Usher’s syndrome – Life with Disease Systemic sclerosis pulmonary – Trials in Disease Ewing’s sarcoma recurrent – Treatment Lymphangioma – Basic Information Hyperoxaluria – Trials in Disease Basal cell naevus syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Lu Ag09222 Human Serum Albumin Aceclofenac Azd2693 Sodium Methylprednisolone Donepezil Etavopivat Glofitamab M1P Dipotassium Salt Ly3537982 Rezvilutamide Levomepromazine Hydrochloride ACETYLCARNITINE HYDROCHLORIDE Efruxifermin Amantadine Hemisulfate Tucatinib Ertapenem Sodium Gallium (68Ga) Chloride Elritercept Ribonucleic Acid K10 More therapies…

    Learn about Your Condition

    Lymphangioleiomyomatosis Medulloblastoma Myopia Partial seizures Short stature Orthostatic hypotension Asplenia Laryngeal cancer stage III Hyperparathyroidism secondary Immune thrombocytopenia Rectosigmoid cancer Agitation postoperative Medication overuse headache Premature baby Chordoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Capecitabine
    • Gimeracil
    • Olaparib
    The Netherlands

  • A study to evaluate the effectiveness and safety of zasocitinib in children and adolescents with moderate-to-severe plaque psoriasis

    Recruiting

    3 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Zasocitinib
    Germany Italy Poland Spain

  • A study to evaluate the effectiveness and safety of LAD328 in adults with moderate to severe hidradenitis suppurativa

    Recruiting

    2 1 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Sodium Chloride
    Bulgaria France Germany Poland Spain

  • A study to evaluate the effectiveness and safety of BFB759 in adults with moderate to severe hidradenitis suppurativa

    Recruiting

    2 1
    Bulgaria Czechia Germany Poland Spain

  • A study to evaluate the safety of VTx-002 in patients with amyotrophic lateral sclerosis.

    Recruiting

    2 1 1
    Investigated Drugs:
    • Sodium Dihydrogen Phosphate Dihydrate
    • VTX-002
    Belgium The Netherlands Spain

  • Study of Blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute lymphocytic leukaemia
    Investigated Drugs:
    • Idarubicin
    • Methotrexate Sodium
    • Crisantaspase
    Austria Belgium Bulgaria Czechia Denmark Estonia +11
Previous Page
1 … 34 35 36 37 38 … 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!